

2025 Taipei International Breast Cancer Symposium

Right Choice for Right Patient

Room 701BC, Taipei Nangang Exhibition Center, Hall 2

Sat., October 25, 2025

Time	Topic	Speaker	Moderator
08:00-08:30	Registration		
08:30-08:40	Opening Ceremony	Yen-Shen Lu /Fang-Ming Chen	
Keynote Speech			
08:40-09:00	Right Choice Beyond Survival: How Taiwan is Pioneering Quality and Equity in Breast Cancer Care Through Value-Based Reform	Chung-Liang Shih	Ming-Feng Hou
Session (1) Advancing Therapies for High-Risk Population			
09:00-09:30	Early Onset Breast Cancer: Current Knowledge and Gaps	Kyong Hwa Park	King-Jen Chang
09:30-10:00	Role of Platinum in Adjuvant/Neoadjuvant Treatment in TNBC	Joohyuk Sohn	Shyr-Ming Sheen-Chen
10:00-10:40	Redefining the Role of TKIs in HER2-Positive mBC: From Systemic Control to CNS Penetration	Nancy Lin	Tsu-Yi Chao
10:40-11:00	Coffee Break		
Session (2) Elevating Care in HR+/HER2- Breast Cancer			
11:00-11:40	Navigating the Complexities of Treatment in HR+ HER2-Metastatic Breast Cancer: Tailoring CDK4/6 Inhibitors to Meet Individual Patient Needs	Hope S. Rugo	Hsien-Tang Yeh
11:40-12:20	The Practice of Treating HR+/HER2- Early Breast Cancer is Evolving: Boardening the Impact of CDK4/6 Inhibitors	Peter Fasching	Fang-Ming Chen
Luncheon Symposium (1)			
12:20-13:05	Maximizing Treatment Benefit and Overall Survival in HER2-Negative MBC	Hsu-Huan Chou	Dar-Ren Chen
13:05-13:20	Coffee Break		
13:20-14:00	The Sustainable Efficacy of CDK4/6 Inhibitor in HR+/Her2-Node+ High Risk Early Breast Cancer	Michael Gnant	Shin-Cheh Chen
14:00-14:30	Personalized Neo-Adjuvant Strategies for Hormone Receptor-Positive Early Breast Cancer	Marc Thill	Shigehira Saji
14:30-15:10	Choosing Wisely:TS-1 for HR+ EBC	Kun-Ming Rau	Hsien-Kun Chang
15:10-15:30	Coffee Break		
15:30-16:10	Transforming Treatment Landscape of HR+ mBC: Integrating Genomic Biomarkers to Drive Precision Medicine	Naoto T. Ueno	Chiun-Sheng Huang
16:10-16:50	The Next Wave of Endocrine and Target Therapy for HR+/HER2- Metastatic Breast Cancer	Peter Schmid	Ling-Ming Tseng
Session (3) Expanding the Horizons of HER2+ Metastatic Breast Cancer Treatment			
16:50-17:30	Unlocking the Potential of ADC: Transforming Breast Cancer Outcomes Across HER2 Expression Spectrum (MBC)	Naoto T. Ueno	Yen-Shen Lu
17:30-18:00	Current Status and Emerging Approaches in HER2+ Metastatic Breast Cancer	Giampaolo Bianchini	Ta-Chung Chao

2025 Taipei International Breast Cancer Symposium

Right Choice for Right Patient

Room 701BC, Taipei Nangang Exhibition Center, Hall 2

Sun., October 26, 2025

Time	Topic	Speaker	Moderator
Breakfast Symposium			
08:10-08:50	Beyond Cancer-Related Fatigue: Exploring Immunomodulatory Strategies to Reshape Breast Cancer Care	Ming-Shen Dai	Kun-Ming Rau
Session (4) Evolving Role of Breast Surgery			
08:50-09:20	The Surgeon's Role in Locoregional Management of Stage IV Breast Cancer	Mehra Golshan	石川孝
09:20-09:50	Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy	Judy C. Boughey	Jyh-Cherng Yu
09:50-10:05	Coffee Break		
10:05-10:35	Omission of Radiation Therapy Post Breast Conserving Surgery	Boon Chua	Shou-Tung Chen
10:35-11:05	Setting the Standard for the Future of Cancer Surgery	Kelly Hunt	Fiona Tsui-Fen Cheng
Session (5) Innovations in mTNBC: Redefining Frontline Treatment with Immunotherapy and ADCs			
11:05-11:45	Shifting Paradigms in mTNBC - Advancing Sacituzumab Towards the Frontline	Sherene Loi	Chin-Yao Lin
11:45-12:25	A New Era in the Treatment of Metastatic Triple-Negative Breast Cancer: Who, When, and Why to Use Immunotherapy and Antibody-Drug Conjugates	Sung-Bae Kim	Chun-Yu Liu
Luncheon Symposium (2)			
12:25-13:10	Advances in Dual HER2 Inhibition: Shaping the Future of HER2-Positive Breast Cancer Care	Chih-Chiang Hung	Ming-Yang Wang
13:10-13:30	Coffee Break		
Session (6) Advancing Therapeutic Strategies and Accessibility in HER2-Positive Breast Cancer: From Early Management to Metastatic Care			
13:30-14:10	Breaking the Ceiling: Strategies to Reduce Recurrence in HER2+ Early Breast Cancer	Chi-Cheng Huang	Yuan-Ching Chang
14:10-14:50	HER2+ Breast Cancer in the Era of Biosimilars: Optimizing Access with Herzuma	Ching-Ting Wei	Chao-Ming Hung
14:50-15:05	Coffee Break		
15:05-15:45	Optimizing HER2 Management Among Breast Cancer Patients: Role of Trastuzumab in Evolving Therapeutic Paradigms	Paul Cornes	Wen-Hung Kuo
15:45-16:25	From Evidence to Action: Impact of Xgeva in Breast Cancer Bone Metastasis	I-Chen Tsai	Kuo-Ting Lee
16:25-16:45	Award Ceremony		
16:45-17:00	Closing		Yen-Shen Lu

2025 Taipei International Breast Cancer Symposium

TBCS-GBCC Joint Session: When East Meets West: Navigating Evolving Breast Cancer Care

Room 701D, Taipei Nangang Exhibition Center, Hall 2

Sat., October 25, 2025

Time	Topic	Speaker	Moderator
10:10-10:30	Axillary management following NAC: Surgical Oncologists' point of views	Jai Min Ryu	Guo-Shiou Liao Wonshik Han
10:30-10:50	Axillary management following NAC: Medical Oncologists' point of views	Sung Hoon Sim	
10:50-11:10	Axillary management following NAC: Radiation Oncologists' point of views	Tzu-Yu Lai	
11:10-11:30	Wrap up: Current guidelines of Axillary management following NAC	Judy C. Boughey	
11:30-12:00	Axillary management following NAC: Surgical Oncologists' point of views	ALL	
12:10-12:50	Please Proceed to Room 701BC for the Lunch Symposium		

2025 Taipei International Breast Cancer Symposium

Young Doctors Forum & Young Doctors Debate

Room 701D, Taipei Nangang Exhibition Center, Hall 2

Sat., October 25, 2025

Young Doctors Forum (YDF)

14:00-14:05	Opening	Chi-Cheng Huang
14:05-14:30	Beyond the White Coat: Challenges Facing Young Female Breast Oncologists and How to Address Them	Kelly Hunt
14:30-14:55	Global Perspectives: Navigating Career Pathways in Breast Cancer Treatment for Young Doctors	Tristen Park
14:55-15:00	Q&A	ALL
15:00-15:05	Break	

Young Doctors Debate (YDD)

15:05-15:45	In this scenario, should ALND be omitted based on current evidence, or is completion ALND still necessary to ensure adequate staging and local control?	YDF Invitees	Chiao Lo
15:45-16:25	Should adjuvant chemotherapy be avoided in this patient given her low recurrence score, despite the presence of nodal micrometastasis?		Chun-Yu Liu
16:25-16:30	QA & Closing	Jeong Eon Lee	
16:30-	Group Photo	ALL	

2025 Taipei International Breast Cancer Symposium

Mini-Symposium

Room 701A, Taipei Nangang Exhibition Center, Hall 2

Sun., October 26, 2025

Time	Topic	Speaker	Moderator
09:35 -10:15	TBD	Chih-Hao Huang	Chih-Chiang Hung
10:15-10:55	New Horizons in First-Line Management of HR+ mBC with PIK3CA Mutation	Shih-Che Shen	Yan-Ang Chen
10:55-11:35	Immunotherapy in Early TNBC: Evolving Evidence, Maximizing Benefit Through Thoughtful Patient Selection	Han-Fang Cheng	Ling-Ming Tseng
11:35-12:15	Suture Scaffold Technique in Breast-Conserving Surgery: Safety, Cosmetic Outcomes, and Lessons from Over 2,000 Cases	Reiko Mitsueda	Chen-Hsiang Chang
12:15-13:10	Luncheon Symposium Treatment Strategies and Sequencing After ET + CDK4/6i for Patients With ER+/HER2- Metastatic Breast Cancer	Soo Chin Lee	Wei-Pang Chung
13:10-13:50	Not all CDK4/6i are created equal: Optimizing HR+ HER2- Metastatic Breast Cancer Treatment Outcomes	Michael Gnant	Ching-Hung Lin
13:50-14:30	Oncofertility Needs and Supportive Care for Breast Cancer Women in Reproductive Age: The Experience from Hope Foundation for Cancer Care in Taiwan	Shiuyu Katie C. Lee	Yao-Jen Chang
14:30-15:10	Survivorship in Breast Cancer: Physical Activity and Alcohol Consumption and Breast Cancer	Tristen Park	Liang-Chih Liu
15:10-15:50	Cardio-Oncology at NCKUH: Breast Cancer and Cardiotoxicity - Progress and Future Directions	Yu-Ling Hsu	Chin-Sheng Hung



2025 台北國際乳癌研討會報名表

10月25日~10月26日(六~日)南港展覽館2館7樓

一、基本資料(以下資料缺一不可,請務必填寫字跡工整,以免建檔有誤影響您的權利,不敷使用,請自行影印)

二、乳醫會員若資料沒有變動,請填寫姓名及英文姓名,會員編號及身分證字號即可

姓名: _____ 英文姓名: _____ 會員編號:(如不知可不寫) _____			
身分證字號: _____ 出生年月日: _____ 年 _____ 月 _____ 日 (以上資料請必填入,如遺漏,恕無法完整登錄積分)			
服務醫院: _____		單位: _____ 職稱: _____	
身分別: <input type="checkbox"/> 醫師 <input type="checkbox"/> 藥師 <input type="checkbox"/> 護理師 <input type="checkbox"/> 專科護理師 <input type="checkbox"/> 放射師 <input type="checkbox"/> 醫檢師 <input type="checkbox"/> 其他人員: _____			
收據抬頭:(如需才寫)			
統一編號:(如需才寫)		希望收據開立日期:	
聯絡地址(必填):□□□□□□			
聯絡電話(必填): _____		手機: _____	
電子信箱(必填): _____			
身分別	<input type="checkbox"/> 團體報名價 (即日起~9/30(含))	<input type="checkbox"/> 個人早鳥票價 (即日起~10/15(含))	<input type="checkbox"/> 現場報名價 (10/16~10/26)
<input type="checkbox"/> 乳房醫學會會員	\$900	\$1200	\$1500
<input type="checkbox"/> 非會員醫師(非乳醫會員、廠商)	\$1200	\$1500	\$2000
<input type="checkbox"/> 非會員(包含藥師、護理人員、放射師、住院醫師、醫學系實習生、研究人員等)	\$800	\$1000	\$1200
<p>1. 報名費以匯款日期為主</p> <p>2. 團體報名注意事項</p> <p>1).請自行湊團報,學會無法協助湊團,請注意!團報需湊滿10人(含以上),需「一次一起」E-mail 或傳真報名表並附上繳款收據至學會,不限同家醫院,不限同種身分別,湊滿10人即團報價。 傳真完請務必來電確認是否報名成功。已繳交團報名單後,事後再追加名單(低於10人),則以個人早鳥價算(至10/15止)。</p> <p>2).每人都需填寫報名表,以上資料都需填寫完成並附上繳費收據,再一起傳真。</p> <p>3. 報名表與匯款單收據須同時傳真或E-mail才算報名成功。</p> <p>4. 不接受之前已繳個人報名費,後續要求再湊團報價退費。</p>			

二、繳費方式:

請至郵局郵政劃撥:50027647,戶名:台灣乳房醫學會,註明:報名10/25-10/26 2025 台北國際乳癌研討會

會

三、退費規定:因故無法參加,10/1(三)前(含)申請,全額退費,10/1(三)後~10/15(三)前申請退費,將核退報名費80%,10/16(四)後申請,恕不退費,謝謝您的配合。(學會將配合政府因應疫情而有所變動,最新公告將會更新在學會網站)

1. 學會開立之收據,將於學員報到當日給予,若需提前拿到收據或開立統編,請在務必在報名表上註明
2. 學會會議結束後將於20天~1個月內將積分整理上傳,如緊急缺積分,無法配合提早上傳,若因個人原因誤簽或簽名難以辨識,請自行負責,敬請見諒
繳費收據黏貼處,或貼在報名表不遮住基本資料即可,請務必將繳費收據註明姓名(可以多人共同劃撥,但請註明參加者姓名,再傳真報名02-25238870,未附黏貼者,視同報名)